IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

Read the article

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

Read the article

IDL Biotech continues its work on automating the TPS® tumor marker

As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the first phase has been completed. Thus, the last phase before launch now begins. The hope is that the product will be available on the Chinese market by the end of 2021.

Read the article

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

“IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

Read the article

IDL Biotech AB has appointed a new CEO

Gunnar Wahlberg was appointed as the new CEO of IDL Biotech from the 1st of December 2020. Gunnar has served as acting CEO since the 1st of September after the previous CEO left the post on the 31st of August. Gunnar Wahlberg has previously been a part of IDL Biotech group executive board and worked as Head of Sales since spring of 2019.

Read the article

IDL Biotech is planning for clinical studies in the United States of America for its rapid diagnostic test for bladder cancer, UBC® Rapid.

In 2019, IDL Biotech submitted a so-called “Pre-submission request” to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the company’s rapid diagnostic test for bladder cancer. As of now, the company is proceeding with preparations of clinical trial in the United States of America.

Read the article

Information from the Annual General Meeting

The Annual General meeting was held on the 28th of May 2019.

Read the article

Christmas Holiday

We would like to inform you that our office will be closed, due to Christmas and New Years Holidays during the following period December 22nd 2019 to January 5th, 2020. Full operations will resume on January the 6th.

Read the article

Meet us

IDL will attend the following meetings during autumn 2018

Read the article

Patent approved in Europe

During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.

Read the article

Articles

Latest News

December 2020

IDL Biotech develops rapid test for breast cancer

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues its work on automating the TPS® tumor marker

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

IDL Biotech AB has appointed a new CEO

IDL Biotech is planning for clinical studies in the United States of America for its rapid diagnostic test for bladder cancer, UBC® Rapid.

Information from the Annual General Meeting

Christmas Holiday

Meet us

Patent approved in Europe